Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene : introduces an exclusive diagnostic system for diagnosing COVID-19 variants at ECCMID

05/23/2021 | 08:30pm EDT

SEOUL, Korea, May 23, 2021 /CNW/ -- Seegene Inc. (KQ 096530), a biotechnology firm specializing in molecular diagnostics has once again been recognized for its unique system for diagnosing COVID-19 variants at this year's European Congress of Clinical Microbiology, the ECCMID.

Logo (PRNewsfoto/Seegene Inc.)

Seegene's Dr. Guy Willem Lee, Director of Marketing Strategy introduced the diagnostic system under the theme of "SARS-CoV-2 and Variants 'Full Screening' Solution" using its latest COVID-19 variant diagnostic tests. "The backdrop of Korea's outstanding control at the onset of the pandemic is because of the one-platform diagnostic system that enables mass testing," said Lee. He added that "the system enabled the diagnostic process from sample collection through PCR testing all at once, helping local authorities to quickly control the pandemic."

The effectiveness of the current diagnostic system, however had been put to question due to a growing number of COVID-19 variants spreading fast, with reports saying vaccines may not offer enough protection against them. The Centers for Diseases Control and Prevention have previously said variants are poised to drive an increase in new cases in the U.S. in May after having projected that the global COVID-19 cases will sharply increase over the continuous surge in variants.

Referring to Seegene's 'Full Screening Solution,' Director Lee proposed that the system will efficiently help counter the protracted COVID-19 pandemic. The 'Full Screening Solution' is a one-step system that can verify whether an individual has contracted coronavirus wildtype or the virus variant with a single real-time PCR test. Currently, health authorities are forced to go through an extra round of genomic sequencing to distinguish the existence of COVID-19 variants after standard PCR tests, automatically leading to a more prolonged testing time.

Against the backdrop of Seegene's 'Full Screening Solution' are the company's latest variant diagnostic tests, the AllplexTM SARS-CoV-2 Master Assay and AllplexTM SARS-CoV-2 Variants I Assay. The AllplexTM SARS-CoV-2 Master is an ideal way of screening for the COVID-19, as it provides results of whether a person is positive of the COVID-19 or even its variants. After an initial round of testing, Seegene's AllplexTM SARS-CoV-2 Variants I Assay will help identify multiple mutant variations in a single reaction.

The AllplexTM SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes (E gene, RdRP gene, N gene and S gene) as well as five defined virus variants notably spotted in the most recognized lineages including B1.1.7, B.1.351, P.1 and B.1.1.207. Seegene's variant diagnostic test is the first such kind to simultaneously detect multiple coronavirus genes and differentiate virus variations, including those found to be more contagious and fatal. It's an ideal and an economic way of screening coronavirus genes as the pandemic continues to rage with both the wildtype and its virus variants. Director Lee added "Seegene's 'Full Screening Solution' will play a critical role in controlling the spread of COVID-19 pandemic amid fast spreading virus variants."

Also at this year's world scientific symposia, Dr. Nakmoon Sung of Seegene Medical Foundation announced outcomes of clinical researches on the detection of SARS-CoV-2 mutations, known to be associated with the variants, as well as the detection of coinfections with respiratory pathogens among COVID-19 patients. Among the COVID-19 positive cases, the proportion of SARS-CoV-2 with the COVID-19 variant associated mutations have surged to 3.5% in late February from the 1.2% a month earlier. Such clinical researches show that Seegene's diagnostic tests are capable of screening COVID-19 and screen for variants with single PCR test. Looking at the coinfection cases, 8.8% of COVID-19 positive cases have also been coinfected with respiratory diseases including Flu A, RSV, rhinovirus, metapneumovirus and Mycoplasma pneumoniae.

Reflecting on the clinical data, Dr. Sung said "swift diagnostic system is extremely critical in helping to control the resurgence of the COVID-19 pandemic," and added that "the one-step and accurate diagnostics will become the global standard in detecting coronavirus and other respiratory diseases, for the purpose of accurate treatment".

View original content to download multimedia:http://www.prnewswire.com/news-releases/seegene-introduces-an-exclusive-diagnostic-system-for-diagnosing-covid-19-variants-at-eccmid-301297361.html

SOURCE Seegene

© Canada Newswire, source Canada Newswire English

All news about SEEGENE, INC.
09/01SEEGENE : Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four C..
08/18SEEGENE : Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
08/18Seegene Inc. Reports Earnings Results for the Second Quarter and First Half Ended June ..
07/13SEEGENE : Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Vari..
07/13Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Var..
07/06SEEGENE : announces partnership with Bio-Rad to develop diagnostic testing products for th..
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
06/29SEEGENE : unveils "MOBILE STATION," for on-site routine testing at public-use facilities a..
06/29Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at th..
More news
Sales 2021 1 244 B 1,06 B 1,06 B
Net income 2021 486 B 0,41 B 0,41 B
Net Debt 2021 - - -
P/E ratio 2021 6,96x
Yield 2021 5,79%
Capitalization 3 356 B 2 861 M 2 850 M
Capi. / Sales 2021 2,70x
Capi. / Sales 2022 4,70x
Nbr of Employees 833
Free-Float 67,9%
Duration : Period :
Seegene, Inc. Technical Analysis Chart | A096530 | KR7096530001 | MarketScreener
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 64 800,00 KRW
Average target price 89 000,00 KRW
Spread / Average Target 37,3%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Hong-Il Yoon Independent Director
Chang-Se Lee Independent Director
Kyung-Jun Chun Director
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-32.85%2 861
BGI GENOMICS CO., LTD.-28.49%5 845